Profil Institute Announces Metabolism Focused ‘Discover & Translate’ Partnership with Gubra

Profil Institute Announces Metabolism Focused ‘Discover & Translate’ Partnership with Gubra

Two renowned metabolic clinical research companies – one focused on preclinical research and discovery, the other on translational clinical research – join forces to validate novel compounds for diabetes, obesity and NAFLD/NASH

SAN DIEGO, June 4, 2015 /PRNewswire/ –  Profil Institute for Clinical Research, an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a strategic collaboration with Gubra ApS, a metabolic preclinical and drug discovery company, to combine expertise and resources to discover and translate into clinical research novel drug targets, compounds and biomarkers addressing metabolic disease.

According to the terms of the collaboration, Gubra will provide metabolic drug discovery expertise and pre-clinical target validation, as well as preclinical services, including in vivo pharmacology, histology and stereology, molecular biology, and assay development.  Profil Institute will provide early phase clinical services, regulatory management, and execution of clinical studies based on compound specific target product profiling and clinical development planning.

Both companies are members of the Profil Institute founded Metabolic Research Partners™ network, an alliance of science and quality driven metabolism focused services providers to the biopharmaceutical and venture capital industries.

”We are delighted at the prospect of working with Profil Institute, bringing together their clinical development and regulatory planning expertise with Gubra´s preclinical skills and know-how”, said Dr. Niels Vrang, Gubra CEO. “Not only is the complementarity between our companies nearly perfect, but we also find that the physical bridging of US and Europe biotech companies in collaborations like this has the potential to unlock ideas and opportunities that either company could not do by themselves. Additionally, for Gubra this collaboration not only consolidates the development of our early drug discovery candidates, but has the potential to boost our current target discovery programs in CNS obesity and NASH/NAFLD.”

“Gubra and Profil Institute are two leading science driven organizations, solely focused on metabolism, addressing adjacent stages of the drug development process.  Individually, the two companies have unrivaled expertise and experience in their specific stages of metabolic research and development,” said Dr. Marcus Hompesch, Profil Institute CEO.  “Together, we will contribute to highly efficient and effective metabolic drug development through meaningful science, advanced methodologies, and a combined team of experts.”

About Gubra ApS
Gubra is a privately-held biotech company in Hørsholm, Denmark. Gubra’s focus is diabetes, obesity, and related metabolic disorders. Within these core areas, Gubra delivers preclinical in vivo, in vitro and histology services to their partners. In addition to the CRO services, Gubra has several active early target, biomarker and peptide discovery programs. For more information, visit www.gubra.dk.

About Profil Institute for Clinical Research, Inc.
Profil Institute is an early engagement clinical research organization (CRO) exclusively focused on metabolic diseases, including diabetes, obesity and NAFLD/NASH. The company is recognized globally for its scientific expertise, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes.  Profil Institute provides a full scope of CRO services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.

Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices.  The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.

Profil Institute is also widely recognized as an innovator of methodologies, including its Automated Glucose Clamp technology, and for driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners. For more information, visit www.profilinstitute.com.

For further information, please contact:

Abby Devine
Profil Institute for Clinical Research, Inc.
Corporate Communications
abby.devine@profilinstitute.com
+1 (858) 663-6148

Niels Vrang
Gubra ApS
niels@gubra.dk
+45 3152 2651